What non‑estrogen topical medications can be used to treat vaginal atrophy?

Non-Estrogen Topical Medications for Vaginal Atrophy

For non-estrogen topical treatment of vaginal atrophy, vaginal DHEA (prasterone) is the primary FDA-approved prescription option, while over-the-counter vaginal moisturizers containing hyaluronic acid represent effective non-hormonal alternatives.

Primary Non-Estrogen Topical Options

Vaginal DHEA (Prasterone)

• Vaginal DHEA is an FDA-approved androgen-based topical therapy that effectively reduces dyspareunia and improves vaginal atrophy symptoms 1
• A randomized controlled trial of 464 breast and gynecologic cancer survivors demonstrated significant improvements in sexual desire, arousal, pain, and overall sexual function 1
• Important caveat: Use with caution in patients on aromatase inhibitor therapy, as vaginal DHEA increases circulating androgens that may potentially impact AI activity 1
• Safety data in survivors of hormonally mediated cancers remains limited 1

Over-the-Counter Vaginal Moisturizers

• Non-hormonal vaginal lubricants and moisturizers (such as Replens) are helpful first-line options, though not as effective as topical estrogens 1
• Hyaluronic acid-based vaginal products show comparable efficacy to estrogen in some studies, with significant improvement in vaginal dryness, itching, dyspareunia, and vaginal pH 2, 3, 4, 5
• A 12-week trial demonstrated that hyaluronic acid cream significantly reduced VVA symptoms with superior tolerability compared to vaginal gels 3
• Formulations combining hyaluronic acid with collagen, isoflavones, and vitamins showed significant improvement in vaginal dryness, vulvovaginal itching, and dyspareunia over 12 weeks 4

Oral Non-Estrogen Option (Not Topical, But Relevant)

Ospemifene

• Ospemifene is an FDA-approved oral selective estrogen receptor modulator (SERM) that effectively treats vaginal dryness and dyspareunia 1
• Large trials demonstrate efficacy in postmenopausal vulvar and vaginal atrophy 1
• Should be considered for dyspareunia in patients without a history of estrogen-dependent cancers 1
• A prospective study of 52 cervical cancer survivors showed improvements in vaginal health, sexual function, and quality of life 1

Additional Supportive Therapies

Non-Pharmacologic Interventions

• Vaginal dilators may be useful for increasing vaginal depth and accommodation, particularly in patients with vaginal stenosis from pelvic radiation 1
• Pelvic floor physical therapy can improve sexual pain, arousal, lubrication, orgasm, and satisfaction 1
• Evidence for dilators is limited but they allow patients to explore comfort in a non-sexual setting 1

Treatment Algorithm

First-line approach:

• Start with over-the-counter vaginal moisturizers containing hyaluronic acid for mild-to-moderate symptoms 1, 6
• These can be used twice weekly for maintenance 4

Second-line approach:

• If OTC moisturizers are insufficient, prescribe vaginal DHEA (prasterone) for moderate-to-severe symptoms 1, 6
• Screen for aromatase inhibitor use before prescribing DHEA 1

Third-line approach:

• Consider oral ospemifene if topical options fail and patient has no history of estrogen-dependent cancer 1

Adjunctive therapy at any stage:

• Add vaginal dilators for stenosis or penetration difficulties 1
• Refer for pelvic floor physical therapy if pelvic floor dysfunction is suspected 1

Critical Caveats

• Plain moisturizers also improved symptoms in the DHEA trial, suggesting a significant placebo or mechanical effect 1
• Hyaluronic acid products are generally inferior to estrogen in head-to-head comparisons but offer a safe alternative when estrogen cannot be used 2
• In breast cancer survivors, moisturizers and lubricants remain first-line therapy due to safety concerns with hormonal options 6
• Long-term safety data for non-hormonal treatments is limited, requiring ongoing research 7